Endo Pharmaceuticals is up over 75% year-to-date. In late May Shocking The Street predicted a key drug could make the stock a 4-bagger and ENDP has been white hot ever since. ENDP delivered fireworks after announcing Q2 2018 financial results. The stock rose by double-digits, but is now slightly off its 52-week high set shortly after earnings. Shocking The Street believes there are more fireworks ahead:
Endo Pharmaceuticals (ENDP) delivered a Q2 revenue and earnings beat last week, and the fireworks flew. ENDP rose as much s 38% on the day. The stock has pulled back a bit since earnings, but is still up over 80% Y/Y. That said, there is currently a war over drug prices. In my opinion, the U.S. economy is not as strong as President Trump would have the populace believe … Ultimately, ENDP delivered fireworks in Q2. The core business appears to be stabilizing. Management confirmed it expected to accelerate timelines for a key drug. According to Shocking The Street, a premium investment service the Shock Exchange runs in conjunction with Seeking Alpha, investors should buy ENDP now before the fireworks start again.
Jamie Dimon and J.P. MorganChase apparently agree. According the most most recent 13f filings they just tripled their stake in the drug maker.